5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES : RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM